drugset / Trial / NCT01125683
To Evaluate Effects of AZD1446, Placebo and Donepezil in Patients With Alzheimer's Disease
RandomizedCrossoverQuadruple-blindBasic science
Summary
The purpose of this study is to evaluate whether treatment with single and multiple oral doses of AZD1446 for 1 week will have effect on Quantified Electroencephalography and Event-Related Potentials in patients with Alzheimers Disease. The total treatment period is 9 weeks, divided into 5 equally long sub-periods of 7 days and 4 wash-out periods of 7 days each.
Timeline
- Start
- 2010-06
- Primary completion
- 2011-03
- Completion
- 2011-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AZD1446 | Small molecule | 2.5 mg | Oral |
| Subject | AZD1446 | Small molecule | 60 mg | Oral |
| Comparator | Donepezil | Small molecule | 5 mg | Oral |